The New York Times - Business:
The modest benefits of the treatment, donanemab, made by Eli Lilly, outweigh the risks, the panel concluded unanimously.
This post first appeared in The New York Times - Business. Read the original article.
Advisory Panel of Experts Endorses F.D.A. Approval of New Alzheimer’s Drug
